CoChat

Bronchiolitis obliterans syndrome–free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis

Open access
Kulkarni, Hrishikesh S., Cherikh, Wida S., Chambers, Daniel C., Garcia, Victoria C., Hachem, Ramsey R., Kreisel, Daniel, Puri, Varun, Kozower, Benjamin D., Byers, Derek E., Witt, Chad A., Alexander-Brett, Jennifer, Aguilar, Patrick R., Tague, Laneshia K., Furuya, Yuka, Patterson, G. Alec, Trulock, Elbert P., Yusen, Roger D. · 2019 · The Journal of Heart and Lung Transplantation
Cited by 134

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: Lung transplant (LTx) recipients have low long-term survival and a high incidence of bronchiolitis-obliterans syndrome (BOS). However, few long-term, multicenter, and precise estimates of BOS-free survival (a composite outcome of death and BOS) incidence exist. Methods: This retrospective cohort study of primary LTx recipients (1994–2011) reported to the ISHLT Thoracic Transplant Registry assessed outcomes through 2012. For the composite primary outcome of BOS-free survival, we used Kaplan-Meier survival and Cox proportional hazards regression, censoring for loss-to-follow-up, end-of-study, and retransplantation. While standard Registry analyses censor at the last consecutive annual complete BOS status report, our analyses allowed for partially missing BOS data. Results: Due to BOS reporting standards, 99.1% of the cohort received LTx in North America. During 79,896 person-years of follow-up, single LTx (6,599/15,268; 43%) and bilateral LTx (8,699/15,268; 57%) recipients had a median BOS-free survival of 3.16 (95% CI, 2.99–3.30) years and 3.58 (95% CI, 3.53–3.72) years, respectively. Almost 90% of the single and bilateral LTx recipients developed the composite outcome within 10 years of transplantation. Standard Registry analyses “overestimated” median BOS-free survival by 0.42 years and “underestimated” the median survival after BOS by about a half-year for both single and bilateral LTx (p<0.05). Conclusions: A majority of LTx recipients die or develop BOS within 4 years, and very few remain alive and free from BOS at 10 years post-transplantation. Less inclusive Registry analytic methods tend to overestimate BOS-free survival. The Registry would benefit from improved international reporting of BOS and other chronic lung allograft dysfunction (CLAD) events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.healun.2018.09.016

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 134

Metadata

Authors
Kulkarni, H. S., Cherikh, W. S., Chambers, D. C., Garcia, V. C., Hachem, R. R., Kreisel, D., Puri, V., Kozower, B. D., Byers, D. E., Witt, C. A., Alexander-Brett, J., Aguilar, P. R., Tague, L. K., Furuya, Y., Patterson, G. A., Trulock, E. P., & Yusen, R. D.
Venue
The Journal of Heart and Lung Transplantation
Publisher
Elsevier BV
Published
2019-01
Volume
38
Issue
1
Pages
5-16
ISSN
1053-2498 (ISSN-L)
OpenAlex
W2892500428
Cited by
134
References
1
FWCI
13.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bronchiolitis obliterans syndrome–free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis. https://app.cochat.ai/papers/10.1016/j.healun.2018.09.016
The paper
Kulkarni, H. S., Cherikh, W. S., Chambers, D. C., Garcia, V. C., Hachem, R. R., Kreisel, D., Puri, V., Kozower, B. D., Byers, D. E., Witt, C. A., Alexander-Brett, J., Aguilar, P. R., Tague, L. K., Furuya, Y., Patterson, G. A., Trulock, E. P., & Yusen, R. D. (2019). Bronchiolitis obliterans syndrome–free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2018.09.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.